<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="motornoron_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="motornoron_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>AM&#304;YOTROF&#304;K LATERAL SKLEROZ</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:Cambria;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{margin-top:24.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	line-height:115%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:14.0pt;
	font-family:Cambria;
	color:#365F91;}
span.char
	{mso-style-name:char;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-hansi-font-family:Cambria;
	color:#365F91;
	font-weight:bold;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:793254077;
	mso-list-template-ids:-288969630;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1
	{mso-list-id:1476482498;
	mso-list-template-ids:-1843752566;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l2
	{mso-list-id:1830709959;
	mso-list-template-ids:1301283394;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l3
	{mso-list-id:2019648767;
	mso-list-template-ids:-1386156746;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal><b><span lang=TR style='font-size:16.0pt;font-family:Tahoma;
mso-ansi-language:TR'>AM&#304;YOTROF&#304;K LATERAL SKLEROZ</span></b><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:14.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ye&#351;im PARMAN, Co&#351;kun �ZDEM&#304;R</span></b><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Son g�ncelleme tarihi: 05. 05. 2009</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

</div>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>Giri&#351; ve <span
class=SpellE>Epidemiyoloji</span></span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
class=SpellE><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Amiyotrofik</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <span class=SpellE>Lateral</span>
Skleroz (ALS), di&#287;er ad&#305;yla motor n�ron hastal&#305;&#287;&#305;
(MNH) <span class=SpellE>primer</span> motor <span class=SpellE>korteks</span>,
<span class=SpellE>beyinsap&#305;</span> ve <span class=SpellE>medulla</span> <span
class=SpellE>spinalisteki</span> motor n�ronlar&#305;n dejenerasyonuyla kendini
g�steren ilerleyici, �l�mc�l bir hastal&#305;kt&#305;r. <span class=SpellE>Kortikospinal</span>
yollar, <span class=SpellE>beyinsap&#305;</span> ve <span class=SpellE>spinal</span>
motor n�ronlar&#305;n t�m�n�n tutulumu klinik tabloyu ve <span class=SpellE>prognozu</span>
belirlemekle birlikte, &nbsp;�zellikle �l�me neden olan <span class=SpellE>spinal</span>
motor n�ronlar&#305;n dejenerasyonu sonucu solunum kaslar&#305;n&#305;n
tutulmas&#305;d&#305;r. Bir�ok Avrupa ve Kuzey Amerika
�al&#305;&#351;mas&#305;nda <span class=SpellE>ALS�nin</span> <span
class=SpellE>insidensi</span> 1-3/100 000 olarak bildirilirken, <span
class=SpellE>prevalans&#305;</span> ise y&#305;lda 4-6/100 000�d&#305;r.
D�nyada yakla&#351;&#305;k 90-100 bin, T�rkiye�de ise 3500-5000 ALS
hastas&#305; oldu&#287;u d�&#351;�n�lmektedir. Nedeni bilinmemekle birlikte
Do&#287;u <span class=SpellE>Pasifikte</span> <span class=SpellE>Guam</span>
Adas&#305;nda, Japonya�da <span class=SpellE>Kii</span> Yar&#305;madas&#305;nda
ve Yeni Gine�de Bat&#305; <span class=SpellE>Papua</span> gibi baz&#305;
co&#287;rafi b�lgelerde <span class=SpellE>insidens</span> ve <span
class=SpellE>prevalans&#305;n&#305;n</span> d�nyan&#305;n di&#287;er
b�lgelerine g�re daha y�ksek oldu&#287;u bildirilmektedir. ALS <span
class=SpellE>nin</span> <span class=SpellE>insidensi</span> ya&#351;la artar;
40 ya&#351;tan �nce d�&#351;�k, 75&nbsp; ya&#351; civar&#305;nda ise en
y�ksektir. Erkekler kad&#305;nlardan daha �ok etkilenir. <span class=SpellE>Bulber</span>
ba&#351;lang&#305;�l&#305; ALS ya&#351;l&#305; hastalarda, �zellikle de
kad&#305;nlarda daha s&#305;kt&#305;r. <span class=SpellE>Sporadik</span> <span
class=SpellE>ALS�nin</span> bir�ok �al&#305;&#351;mada ortalama
ba&#351;lang&#305;� ya&#351;&#305; 60-65 aras&#305;nda de&#287;i&#351;mektedir,
ailevi olanda ise ortalama ba&#351;lang&#305;� ya&#351;&#305; bundan bir <span
class=SpellE>dekad</span> �ncedir. �ok nadir olarak 2 ve 3. <span class=SpellE>dekadda</span>
da g�r�lebilir. <span class=SpellE>Sporadik</span> <span class=SpellE>ALS�de</span>
erkek/kad&#305;n oran&#305; 1.5/1 iken, ailevi <span class=SpellE>ALS�de</span>
bu oran 1/1 <span class=SpellE>dir</span>. Ailevi olgular t�m hasta grubunun
%10�nu olu&#351;turur. Ailevi ALS hastalar&#305;nda tan&#305;mlanan ilk gen 21.
kromozomda bulunan <span class=SpellE><i>superoksit</i></span><i> <span
class=SpellE>dismutaz</span> 1 </i>(SOD1) genidir. SOD1, t�m ailevi
olgular&#305;n yakla&#351;&#305;k % 5�inden sorumludur ve g�n�m�ze kadar
130�dan fazla mutasyon tan&#305;mlanm&#305;&#351;t&#305;r. Ailevi ve <span
class=SpellE>sporadik</span> olgular aras&#305;nda, klinik tablo ve <span
class=SpellE>n�ropatolojik</span> bulgular a�&#305;s&#305;ndan belirgin farklar
g�zlenmemektedir. Ailevi ve <span class=SpellE>sporadik</span> <span
class=SpellE>ALS�de</span> g�r�len motor n�ron dejenerasyonunun ortak molek�ler
mekanizmay&#305; payla&#351;t&#305;&#287;&#305; d�&#351;�n�lmektedir. Bu
nedenle genetik �al&#305;&#351;malar sayesinde olu&#351;turulan <span
class=SpellE>transgenik</span> hayvan modelleri hastal&#305;&#287;&#305;n <span
class=SpellE>etyopatogenezinin</span> anla&#351;&#305;labilmesine ve tedavi
perspektiflerinin olu&#351;turulabilmesine katk&#305;da bulunacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Baz&#305; fakt�rlerin ALS
olu&#351;umunda etkili oldu&#287;u ileri s�r�lm�&#351;t�r. Bunlar&#305;n
aras&#305;nda travma, egzersiz, diyet, E vitamini al&#305;m&#305;, &#351;ehirde
ya&#351;amak, alkol t�ketimi, sigara i�mek, deri ve elektrikle ilintili sanayi
alanlar&#305;nda �al&#305;&#351;mak say&#305;labilir. Ge�irilmi&#351; <span
class=SpellE>poliomiyelit</span> gibi <span class=SpellE>viral</span> <span
class=SpellE>infeksiyonlar&#305;n</span> etken olabilece&#287;i �ne s�r�lse de
kesin kan&#305;t bulunamam&#305;&#351;t&#305;r. Baz&#305; meslek
gruplar&#305;nda <span class=SpellE>ALS�ye</span> rastlanma oran&#305;n&#305;n
y�ksek olabilece&#287;i g�zlenmi&#351;tir. �rne&#287;in Birinci K�rfez
Sava&#351;&#305;nda (A&#287;ustos 1990-Temmuz 1991) g�rev yapan Amerikan Ordusu
askerleri aras&#305;nda yap&#305;lan bir ara&#351;t&#305;rmada <span
class=SpellE>ALS�ye</span> rastlanma oran&#305; olduk�a y�ksek bulunmu&#351;,
ard&#305;ndan askeri personelin ara&#351;t&#305;rma grubunu
olu&#351;turdu&#287;u <span class=SpellE>prospektif</span> �al&#305;&#351;mada
da bu meslek grubunda <span class=SpellE>ALS�den</span> �l�m riskinin y�ksek
oldu&#287;u saptanm&#305;&#351;t&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�al&#305;&#351;malara g�re
sa&#287; kal&#305;m s�resi ALS semptomlar&#305;n&#305;n ba&#351;lamas&#305;ndan
itibaren ortalama 2.5-3.5 y&#305;ld&#305;r. Semptomlar&#305;n ba&#351;lama
b�lgesinin <span class=SpellE>prognozu</span> belirlemede �nemli bir fakt�r
oldu&#287;u da s�ylenmi&#351;tir.&nbsp; Buna g�re ba&#351;lang&#305;�ta <span
class=SpellE>bulber</span> b�lgeye ait semptomlar&#305; olan hastalar&#305;n
sa&#287; kal&#305;m s�resi, <span class=SpellE>ekstremite</span> tutulumu olanlara
g�re daha k&#305;sad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Klinik �zellikler ve Tan&#305;</span></b><span lang=DE style='font-family:
Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>a. Tan&#305; kriterleri</span></b><span
lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�st ve alt motor n�ron tutulumu
bulgular&#305;n&#305;n birlikte bulunmas&#305; <span class=SpellE>ALS�nin</span>
klinik �zelli&#287;idir. �a&#287;&#305;m&#305;zda teknolojinin sundu&#287;u
bir�ok olana&#287;a ra&#287;men ALS tan&#305;s&#305;n&#305;n klinik ve
klini&#287;i destekleyen <span class=SpellE>elektrofizyolojik</span>
bulgular&#305;n bir araya gelmesiyle m�mk�n oldu&#287;unu s�ylemek
yanl&#305;&#351; de&#287;ildir. &#304;yi bir <span class=SpellE>klinisyen</span>
hastal&#305;k �yk�s� ve n�rolojik muayeneyle hastal&#305;&#287;&#305;n
tan&#305;s&#305;n&#305; koyabilir. <span class=SpellE>Elektromiyografinin</span>
(EMG) de yine hastal&#305;k �yk�s� ve klinik muayene &#305;&#351;&#305;&#287;&#305;nda
yap&#305;lmas&#305; son derece �nemlidir. <span class=SpellE>Ay&#305;r&#305;c&#305;</span>
tan&#305;da yer alan di&#287;er hastal&#305;klar i�in gerekli <span
class=SpellE>laboratuvar</span> y�ntemlerine ba&#351;vurulmas&#305; da
gereklidir. Bunlardan ilerde s�z edilecektir. &#304;lk kez 1990 da ALS i�in
tan&#305; kriterleri olu&#351;turulmu&#351;tur. <i>El <span class=SpellE>Escorial</span>
Kriterleri </i>(Madrid yak&#305;nlar&#305;nda toplant&#305;n&#305;n
yap&#305;ld&#305;&#287;&#305; yere atfen) ad&#305; verilen bu kriterlere son
hali 2000 y&#305;l&#305;nda verilmi&#351;tir (<b>Tablo 1</b>). Hastalar&#305;
El <span class=SpellE>Escorial</span> Kriterlerinde yer alan kategorilere g�re
de&#287;erlendirmek, g�nl�k klinik uygulamada pratik olmasa bile, daha �ok
�al&#305;&#351;ma ve ara&#351;t&#305;rmalar i�in bir fikir birli&#287;i
sa&#287;lanmas&#305; a�&#305;s&#305;ndan �nemlidir.<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Tablo 1. G�zden ge�irilmi&#351; El <span class=SpellE>Escorial</span>
tan&#305; kriterleri (<span class=SpellE>Brooks</span> ve ark., 2000)</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>___________________________________________________________________<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>ALS tan&#305;s&#305; i�in gerekli olanlar:</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>A:1 Klinik, <span class=SpellE>elektrofizyolojik</span>
veya <span class=SpellE>histopatolojik</span> olarak alt motor n�ron
tutulumunun kan&#305;tlanmas&#305;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>A:2 Klinik muayene ile �st motor n�ron tutulumunun
kan&#305;tlanmas&#305;</span><span lang=DE style='font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>A:3 �yk� veya muayene ile belirti ve bulgular&#305;n bir
v�cut b�lgesi i�inde <span class=SpellE>ya</span> da di&#287;er b�lgelere
ilerleyici �zellikte yay&#305;lmas&#305;</span><span lang=DE style='font-family:
Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
DE'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Olmamas&#305; gerekenler:</span></b><span lang=DE
style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>B:1 Alt motor n�ron ve/veya �st motor n�ron tutulumunu
a�&#305;klayabilecek ba&#351;ka bir hastal&#305;&#287;&#305; telkin eden <span
class=SpellE>elektrofizyolojik</span> ve <span class=SpellE>histopatolojik</span>
veriler</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>B:2 Var olan&nbsp; klinik ve <span class=SpellE>elektrofizyolojik</span>
bulgular&#305; g�r�nt�leme y�ntemleriyle a�&#305;klayabilecek veriler</span><span
lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DE style='font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bu ilkeler �er�evesinde;</span><span style='font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kesin ALS</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l0 level1 lfo1;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>��
     b�lgede �st ve alt motor n�ron bulgular&#305;</span><span lang=DE
     style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DE style='font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Olas&#305; ALS</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l2 level1 lfo2;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;ki
     b�lgede �st ve alt motor n�ron bulgular&#305;yla birlikte en az&#305;ndan
     baz&#305; �st motor n�ron tutulumu bulgular&#305;n&#305;n alt motor n�ron
     tutulumu bulgular&#305;n&#305;n daha �st�nde yer almas&#305;</span><span
     style='font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Olas&#305; ALS-<span class=SpellE>Laboratuvar</span>
destekli</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l3 level1 lfo3;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bir
     <span class=SpellE>ya</span> da birden �ok �st motor n�ron tutulumu
     bulgusu ve EMG ile en az iki b�lgede alt motor n�ron bulgusuna
     rastlanmas&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>M�mk�n ALS</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo4;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bir
     b�lgede �st ve alt motor n�ron bulgular&#305;n&#305;n birlikte
     olmas&#305;,</span><span style='font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo4;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;ki
     <span class=SpellE>ya</span> da daha �ok b�lgede �st motor n�ron
     bulgular&#305;n&#305;n olmas&#305; veya</span><span style='font-family:
     Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo4;tab-stops:list 36.0pt'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�st
     motor n�ron bulgular&#305;n&#305;n alt motor n�ron bulgular&#305;n&#305;n
     �st�nde yer almaks&#305;z&#305;n, iki b�lgede �st ve alt motor n�ron
     bulgular&#305;n&#305;n olmas&#305; </span><span style='font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>___________________________________________________________________________</span></b><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>b. Belirti ve Bulgular</span></b><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
class=SpellE><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ALS�li</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> hastalar&#305;n bir
b�l�m�nde yak&#305;nma ve belirtiler <span class=SpellE>bulber</span> b�lgeden,
di&#287;er bir b�l�m�nde ise taraflardan ba&#351;lar. <span class=SpellE>Bulber</span>
ba&#351;lang&#305;�l&#305; ALS formuna <span class=SpellE>progresif</span> <span
class=SpellE>bulber</span> fel� (<span class=SpellE>palsy</span>) (PBP),
taraflardan ba&#351;layana ise <span class=SpellE>progresif</span> <span
class=SpellE>m�sk�ler</span> <span class=SpellE>atrofi</span> (PMA)&nbsp; de
denir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Bir �ok hastada ilk g�ze �arpan
lokal zaaf ve <span class=SpellE>atrofidir</span>. Hastal&#305;&#287;&#305;n
ba&#351;lang&#305;c&#305;nda baz&#305; hastalar �zellikle gece belirgin olan
kramplardan yak&#305;n&#305;r. Kramplara <span class=SpellE>fasik�lasyonlar</span>
da e&#351;lik edebilir. <span class=SpellE>Fasik�lasyonlar</span> tek <span
class=SpellE>ya</span> da birka� kas grubuna <span class=SpellE>lokalize</span>
olabilece&#287;i gibi tek bir <span class=SpellE>ekstremiteyi</span>
etkileyebilir, t�m v�cuda yay&#305;labilir. <span class=SpellE>Bulber</span>
ba&#351;lang&#305;�l&#305; hastalarda ilk yak&#305;nma genellikle <span
class=SpellE>dizartridir</span>, daha nadir olarak da <span class=SpellE>disfajidir</span>.
<span class=SpellE>Bulber</span> tutulumda alt <span class=SpellE>fasyal</span>
zaaf&#305;n da katk&#305;da bulundu&#287;u <span class=SpellE>nazone</span> bir
konu&#351;ma ve <span class=SpellE>spastik</span> <span class=SpellE>dizartri</span>
kar&#305;&#351;&#305;m&#305;n&#305;n, yani alt ve �st motor n�ron tutulumunun
bulgular&#305; g�ze �arpar. Hastan&#305;n ilk fark etti&#287;i ve dile
getirdi&#287;i yak&#305;nma �ses de&#287;i&#351;ikli&#287;i� <span
class=SpellE>dir</span>. Bu tabloya ayn&#305; anda ba&#351;layan taraf
zaaf&#305; e&#351;lik edebilece&#287;i gibi, <span class=SpellE>bulber</span>
belirti ve bulgular&#305;n ba&#351;lamas&#305;ndan aylar sonra da ortaya
�&#305;kabilir. Dilde zaaf ve <span class=SpellE>atrofi</span>, �zellikle dil
a&#287;&#305;z i�indeyken g�zlenmesi uygun olan <span class=SpellE>fasik�lasyonlar&#305;n</span>
varl&#305;&#287;&#305;, boyun <span class=SpellE>fleksiyon</span> zaaf&#305;
tan&#305; koydurucudur. <span class=SpellE>Orbik�laris</span> <span
class=SpellE>oris</span> zaaf&#305;na ba&#287;l&#305; a&#287;&#305;z kapama
g��l�&#287;�, yumu&#351;ak damak <span class=SpellE>fonasyonla</span> iyi
kalkmasa bile <span class=SpellE>farenks</span> refleksinin kaybolmamas&#305;
genellikle s&#305;k g�r�len belirtilerdir. Ayr&#305;ca �ene refleksinin
varl&#305;&#287;&#305; da ara&#351;t&#305;r&#305;lmal&#305;d&#305;r. Solunum
kaslar&#305;n&#305;n tutulumu <span class=SpellE>bulber</span>
ba&#351;lang&#305;�l&#305; ALS� de de&#287;i&#351;kendir. �stte s�z� edilen alt
<span class=SpellE>fasyal</span> tutulumun sonucu olarak a&#287;&#305;z
kapamadaki zaaf nedeniyle hastalar&#305;n <span class=SpellE>vital</span>
kapasitelerinin de&#287;erlendirilmesi sa&#287;l&#305;kl&#305; bir &#351;ekilde
yap&#305;lamayabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Taraflardan ba&#351;layan ALS�
de ad&#305;ndan da anla&#351;&#305;laca&#287;&#305; gibi kol <span
class=SpellE>ya</span> da bacaklarda, genellikle asimetrik olan zaaf ve <span
class=SpellE>atrofi</span> ortaya �&#305;kar. Zaman i�inde <span class=SpellE>kranyal</span>
sinir tutulumu da tabloya eklenir. Hastalar&#305;n %10-15 kadar&#305;
hastal&#305;&#287;&#305;n son evresine kadar bir miktar <span class=SpellE>dizartri</span>
ve <span class=SpellE>disfajileri</span> olsa da konu&#351;ma yetilerini
kaybetmezler. Buna kar&#351;&#305;l&#305;k erken evrede solunum yetmezli&#287;i
geli&#351;en hastalar da g�r�lebilir. Baz&#305; hastalar uzun bir s�re,
tan&#305; a�&#305;s&#305;ndan zorluk yaratabilecek, �st motor n�ron bulgular&#305;
olmaks&#305;z&#305;n sadece taraf zaaf&#305; ve <span class=SpellE>atrofiyle</span>
kendini g�steren klinik �zellikler sergileyebilirler (<span class=SpellE>ps�do</span>-<span
class=SpellE>polinevritik</span> form). Bu durumda en iyi tutum <span
class=SpellE>ay&#305;r&#305;c&#305;</span> tan&#305;da yer alan
hastal&#305;klar&#305; d&#305;&#351;lad&#305;ktan sonra klinik <span
class=SpellE>izlemdir</span>. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
class=SpellE><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Primer</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <span class=SpellE>lateral</span>
skleroz (PLS) ilerleyici �st motor n�ron tutulumuyla giden bir tablodur. Bu t�r
bir klinik formda ba&#351;layabilen ALS tablolar&#305; olabilece&#287;inden
tan&#305; a�&#305;s&#305;ndan &#351;a&#351;&#305;rt&#305;c&#305; olabilir.
Genel e&#287;ilim 3 y&#305;l PLS tablosuyla giden durumda bu tan&#305;da karar
k&#305;lmakt&#305;r. <span class=SpellE>PLS�nin</span> <span class=SpellE>prognozu</span>
ALS ye g�re �ok daha iyidir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
class=SpellE><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ALS�de</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <span class=SpellE>ok�lomotor</span>
tutulum, <span class=SpellE>sfinkter</span> kusuru, <span class=SpellE>otonomik</span>
ve duysal belirtiler genellikle g�r�lmez. <span class=SpellE>Kognitif</span>
tutulum hastal&#305;&#287;&#305;n ba&#351;lang&#305;c&#305;nda rastlanan bir
�zellik olmamas&#305;na ra&#287;men ALS-<span class=SpellE>demans</span> <span
class=SpellE>sendromunda</span> (t�m ALS hastalar&#305;n&#305;n %5�i) <span
class=SpellE>demans</span> �nde giden bir bulgudur.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>c. <span class=SpellE>Ay&#305;r&#305;c&#305;</span>
Tan&#305;</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
class=SpellE><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ALS�nin</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> <span class=SpellE>ay&#305;r&#305;c&#305;</span>
tan&#305;s&#305;nda yer alan ba&#351;l&#305;ca klinik tablo ve <span
class=SpellE>sendromlar</span> <b>Tablo 2</b>�de yer almaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div style='border:none;border-bottom:solid windowtext 1.5pt;padding:0cm 0cm 1.0pt 0cm'>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 2.&nbsp; <span
class=SpellE>ALS�nin</span> <span class=SpellE>ay&#305;r&#305;c&#305;</span>
tan&#305;s&#305;nda yer alan klinik tablo ve <span class=SpellE>sendromlar</span></span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

</div>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp; Klinik tablo/<span class=SpellE>sendrom</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bulgular/<span class=SpellE>ay&#305;r&#305;c&#305;</span> tan&#305;</span></b><span
lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>___________________________________________________________________________</span></b><span
lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DE
style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kafa taban&#305;-<span
class=SpellE>Kranyoservikal</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<span class=SpellE>Bulber</span> tutulum+uzun <span class=SpellE>traktus</span>
bulgular&#305;</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>bile&#351;ke <span
class=SpellE>lezyonlar&#305;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(MR ve/veya BT ile <span class=SpellE>ay&#305;r&#305;c&#305;</span> tan&#305;
yap&#305;l&#305;r)</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DE
style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span class=SpellE><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Servikal</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
<span class=SpellE>miyelopati</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#304;lerleyici
zaaf+asimetrik AMN bulgular&#305;</span><span lang=DE style='font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(<span class=SpellE>Radik�ler</span> tipte a&#287;r&#305;, <span class=SpellE>bulber</span>
tutulum yoktur</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MR da <span class=SpellE>spinal</span>+ k�k bas&#305;s&#305; bulgular&#305;
olur-en �ok bu</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
tablo ile kar&#305;&#351;&#305;r)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span class=SpellE><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sirengomiyeli</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
�MN+AMN bulgular&#305;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(<span
class=SpellE>Spinal</span> <span class=SpellE>MR�la</span> tan&#305; konur, <span
class=SpellE>ALS�den</span> ayr&#305;l&#305;r)</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span class=SpellE><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nkl�zyon</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> cisim
<span class=SpellE>miyoziti</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;lerleyici zaaf+<span class=SpellE>bulber</span> bulgular+solunum
kaslar&#305;n&#305;n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;tutulumuna ba&#287;l&#305; solunum yetmezli&#287;i </span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(EMG+kas biyopsisiyle <span class=SpellE>ay&#305;r&#305;c&#305;</span>
tan&#305; yap&#305;l&#305;r)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kramp/<span class=SpellE>fasik�lasyon</span>/<span
class=SpellE>miyokimi</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kramplar, baz&#305; durumlarda zaaf&#305;n da e&#351;lik etti&#287;i</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span class=SpellE><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>sendromlar&#305;</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<span class=SpellE>fasik�lasyon</span> ve kas&#305;lmalar , <span class=SpellE>Isaac�s</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<span class=SpellE>Sendromu</span> </span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(EMG ve VGKC antikorlar&#305; ile tan&#305; konur)</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span class=SpellE><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multifokal</span></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> motor
<span class=SpellE>n�ropati</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<span class=SpellE>Fokal</span> asimetrik ba&#351;lar, sadece AMN
bulgular&#305; </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(EMG de motor sinirlerde ileti blo&#287;u, <span class=SpellE>IVIg</span> ile</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;tedaviye
yan&#305;t verir)</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kennedy
Hastal&#305;&#287;&#305;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Erkekleri tutar, yava&#351; ilerleyici <span class=SpellE>bulber</span>+taraf</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(<span class=SpellE>X�e</span>
ba&#287;l&#305; <span class=SpellE>bulbo</span>-<span class=SpellE>spinal</span>
<span class=SpellE>atrofi</span>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
zaaf&#305; </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Aile
�yk�s� + hafif duysal <span class=SpellE>n�ropati</span>+genetik&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div style='border:none;border-bottom:solid windowtext 1.5pt;padding:0cm 0cm 1.0pt 0cm'>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
test-CAG tekrar art&#305;&#351;&#305;- ile tan&#305; konur)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

</div>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar:
�MN �st motor n�ron, AMN alt motor n�ron, MR manyetik rezonans, VGKC voltaja
ba&#287;l&#305; potasyum kanal&#305;.</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 2�</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>de belirtilen hastal&#305;klar
d&#305;&#351;&#305;nda yer alan, <span class=SpellE>ALS�yi</span> taklit
edebilecek <span class=SpellE>ya</span> da ALS ile kar&#305;&#351;abilecek,
daha nadir olarak g�ndeme gelen fakat literat�rde yer alan baz&#305; klinik
tablolardan da s�z etmek gerekmektedir. <span class=SpellE>&#304;nfeksiyona</span>
<span class=SpellE>ya</span> da ba&#351;ka <span class=SpellE>etyolojik</span>
fakt�rlere ba&#287;l&#305; bu hastal&#305;klardan baz&#305;lar&#305; ila�la
tedaviye cevap verdi&#287;i i�in hastan&#305;n klinik tutulumuna, <span
class=SpellE>laboratuvar</span> bulgular&#305;na g�re <span class=SpellE>ay&#305;r&#305;c&#305;</span>
tan&#305;da yer almal&#305;d&#305;r.&nbsp; Bunlardan ba&#351;l&#305;calar&#305;
<i>HTLV1</i> <span class=SpellE>miyelopatisi</span>, HIV <span class=SpellE>infeksiyonu</span>,
<span class=SpellE>poliomiyelit</span>, <span class=SpellE>Lyme</span>
hastal&#305;&#287;&#305; ve kansere ba&#287;l&#305; durumlard&#305;r. HTLV1 <span
class=SpellE>miyelopatisinde</span> bilindi&#287;i gibi yava&#351; ilerleyici, <span
class=SpellE>sfinkter</span> kusurunun da e&#351;lik etti&#287;i <span
class=SpellE>spastik</span> <span class=SpellE>paraparezi</span> ortaya
�&#305;kmaktad&#305;r. Nadir olarak <span class=SpellE>ALS�ye</span> benzer bir
tabloya neden oldu&#287;u da yaz&#305;lm&#305;&#351;t&#305;r. Bu tabloda dil ve
taraflarda <span class=SpellE>fasik�lasyon</span> ve <span class=SpellE>atrofi</span>,
piramidal <span class=SpellE>sendrom</span>, <span class=SpellE>EMG�de</span>
de yayg&#305;n <span class=SpellE>denervasyon</span> bulgular&#305; bulunur. <span
class=SpellE>Sfinkter</span> kusurunun da e&#351;lik etti&#287;i bu klinik
�zelliklere sahip 2 hastada yap&#305;lan otopside ALS ye �zg� <span
class=SpellE>histopatolojik</span> bulgulardan �ok <span class=SpellE>inflamasyona</span>
rastlanm&#305;&#351;t&#305;r. ALS ile aras&#305;nda ili&#351;ki kurulan di&#287;er
<span class=SpellE>infeksiy�z</span> durum <i>HIV</i> ile oland&#305;r. HIV <span
class=SpellE>infeksiyonu</span> ve ALS <span class=SpellE>sendromu</span> olan
bir hastan&#305;n anti-<span class=SpellE>viral</span> tedaviye cevap
verdi&#287;i g�r�lm�&#351;t�r. Buna ra&#287;men <span class=SpellE>HIV�in</span>
<span class=SpellE>ALS�ye</span> benzer tablolarda <span class=SpellE>patojenik</span>
fakt�r oldu&#287;unu s�ylemek i�in elde kan&#305;t yoktur. Bununla birlikte HIV
<span class=SpellE>infeksiyonu</span> a�&#305;s&#305;ndan risk grubunda olan <span
class=SpellE>ALS�li</span> hastalarda HIV <span class=SpellE>serolojisine</span>
bak&#305;lmal&#305;d&#305;r. <span class=SpellE>Polio</span> <span
class=SpellE>infeksiyonu</span> a&#351;&#305;s&#305;na ra&#287;men halen
d�nyada en s&#305;k rastlanan motor n�ron hastal&#305;&#287;&#305;d&#305;r. <span
class=SpellE>Poliodan</span> y&#305;llar sonra ortaya �&#305;kan, <span
class=SpellE>stabil</span> giden �n boynuz hastal&#305;&#287;&#305;n&#305;n
k�t�le&#351;mesiyle karakterize <i>post-<span class=SpellE>polio</span> <span
class=SpellE>sendromu</span></i> ALS ile kar&#305;&#351;abilir. Hastan&#305;n
�z ge�mi&#351;indeki <span class=SpellE>polio</span> �yk�s�, &nbsp;�ok
yava&#351; <span class=SpellE>progresyon</span>, ayr&#305;ca �MN
bulgular&#305;n&#305;n bulunmay&#305;&#351;&#305; ile ALS den
ayr&#305;l&#305;r. <span class=SpellE><i>Lyme</i></span><i>
hastal&#305;&#287;&#305;</i>n&#305;n ilerleyici motor n�ron
hastal&#305;&#287;&#305;na yol a�t&#305;&#287;&#305; bildirilmi&#351;tir. Bir
olgu sunumu &#351;eklinde sunulan tipik ALS tablosu g�steren hastan&#305;n <span
class=SpellE>laboratuvar</span> bulgular&#305; �ok fazla desteklemese de (BOS
proteini normal, h�cre yok, sadece <span class=SpellE>oligoklonal</span>
bantlarda pozitiflik) <span class=SpellE>Lyme</span> hastal&#305;&#287;&#305;
a�&#305;s&#305;ndan <span class=SpellE>endemik</span> bir b�lgede
ya&#351;ad&#305;&#287;&#305; i�in <span class=SpellE>Lyme�a</span> �zg�
antibiyotik tedavisiyle tamam&#305;yla d�zeldi&#287;i bildirilmi&#351;tir. <span
class=SpellE>ALS�yi</span> taklit edebilecek di&#287;er tablolar <span
class=SpellE><i>paraneoplastik</i></span><i> <span class=SpellE>sendromlar<span
style='font-style:normal'>d&#305;r</span></span></i>. Baz&#305; hastalarda
anti-<span class=SpellE>n�ronal</span> antikorlar&#305;n varl&#305;&#287;&#305;
da g�sterilmi&#351;tir. Bunun d&#305;&#351;&#305;nda <span class=SpellE>Hodgkin</span>
ve <span class=SpellE>non</span>-<span class=SpellE>Hodgkin</span> <span
class=SpellE>lenfoma</span>, <span class=SpellE>makroglobulinemi</span>, <span
class=SpellE>miyelom</span> ve <span class=SpellE>POEMS�le</span> de birlikte
bulunabilece&#287;ini g�steren olgu bildirimleri vard&#305;r. Kanser
varl&#305;&#287;&#305;n&#305;n <span class=SpellE>ALS�nin</span> ortaya
�&#305;kmas&#305;nda <span class=SpellE>etyolojik</span> fakt�r
olabilece&#287;ini kan&#305;tlayan kesin bulgular olmasa da,&nbsp; kansere
y�nelik tedaviyle gerileyebilen ALS benzeri tablolar oldu&#287;undan, bu durum
g�z �n�nde bulundurulmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>c. Tan&#305; Y�ntemleri</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>ALS i�in �zg�n bir tan&#305;
y�ntemi <span class=SpellE>ya</span> da <span class=SpellE>laboratuvar</span>
testi yoktur. Genel olarak <span class=SpellE>klinisyenin</span>
yapt&#305;&#287;&#305; <span class=SpellE>ay&#305;r&#305;c&#305;</span>
tan&#305;da yer alan, ALS <span class=SpellE>sendromuna</span> yol a�abilecek,
�zellikle de tedavi edilebilecek hastal&#305;klar&#305;n ortaya konmas&#305;
i�in gerekli olan testler istenmelidir. <span class=SpellE>Elektrofizyolojik</span>
testler (sinir ileti �al&#305;&#351;malar&#305; ve i&#287;ne <span
class=SpellE>EMG�si</span>) yine de en �nemli ara&#351;t&#305;rma y�ntemidir.
Rutinde istenen kan testleri (tam kan say&#305;m&#305;, <span class=SpellE>sedimentasyon</span>,
CPK, elektrolit ve karaci&#287;er enzimleri gibi) ve <span class=SpellE>kranyal</span>
<span class=SpellE>ya</span> da <span class=SpellE>spinal</span> MR
d&#305;&#351;&#305;nda klinik tabloya g�re di&#287;er ba&#351;ka testler de
istenebilir (ayr&#305;nt&#305;s&#305; <b>Tablo 3�</b> de verilmi&#351;tir).<o:p></o:p></span></p>

<div style='border:none;border-bottom:solid windowtext 1.5pt;padding:0cm 0cm 1.0pt 0cm'>

<p class=MsoNormal style='text-align:justify;line-height:200%'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:200%'><b><span
lang=TR style='font-size:10.0pt;line-height:200%;font-family:Tahoma;mso-ansi-language:
TR'>Tablo 3. Rutin incelemeler d&#305;&#351;&#305;nda, klinik tabloya g�re
istenebilecek testler</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

</div>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>1-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Kas biyopsisi</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>2-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>B12-<span
class=SpellE>Folat</span></span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>3-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Kan
gazlar&#305;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>4-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Protein <span
class=SpellE>elektroforezi</span>, <span class=SpellE>immunfiksasyon</span>
y�ntemiyle serum <span class=SpellE>immunelektroforezi</span></span><span
lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>5-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Anti-<span
class=SpellE>n�ronal</span> antikorlar</span><span lang=DE style='font-family:
Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>6-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Ant-<span
class=SpellE>gangliozid</span> antikorlar&#305; (<span class=SpellE>IgM</span>
GM1)</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>7-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>T�m�r belirte�leri</span><span
lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>8-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Toksinler i�im
kan ve/veya idrar tahlili (kur&#351;un, manganez)</span><span lang=DE
style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>9-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>HIV, HTLV1 <span
class=SpellE>serolojisi</span></span><span lang=DE style='font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>10-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp; </span><span class=SpellE><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Lyme</span></span><span lang=TR style='font-size:10.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'> hastal&#305;&#287;&#305; <span
class=SpellE>serolojisi</span></span><span lang=DE style='font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>11-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp; </span><span class=SpellE><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Heksozaminidaz</span></span><span lang=TR style='font-size:10.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'> d�zeyi</span><span
lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%'><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>12-</span><span lang=TR
style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-size:10.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>Genetik test (SOD1 mutasyonu
i�in)</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='text-align:center;line-height:150%'><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-left:18.0pt;text-align:justify;line-height:
150%'><span lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Tedavi Yakla&#351;&#305;mlar&#305;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
class=SpellE><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ALS�nin</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> bug�n i�in ge�erli
tedavisi yoktur. Hastal&#305;&#287;&#305;n <span class=SpellE>etyopatogenezini</span>
ayd&#305;nlatmaya y�nelik bir�ok ara&#351;t&#305;rma var olmas&#305;na
ra&#287;men, yap&#305;lan �al&#305;&#351;malar hastal&#305;&#287;&#305;
�iyile&#351;tirme� y�n�nde olumlu sonu� vermemi&#351;tir. G�n�m�zde �st�nde <span
class=SpellE>yo&#287;unla&#351;&#305;lan</span> tedavi
yakla&#351;&#305;mlar&#305;n&#305;n bir b�l�m� <span class=SpellE>mutant</span>
SOD1�in neden oldu&#287;u motor n�ron dejenerasyonunun olu&#351;
mekanizmas&#305;n&#305; model alm&#305;&#351;t&#305;r. Bir b�l�m
�al&#305;&#351;ma da motor n�ron <span class=SpellE>dejeneresans&#305;na</span>
kadar ge�en s�re�teki etaplar&#305; tek <span class=SpellE>tek</span> g�zden
ge�irip, bu a&#351;amalara m�dahale etmeyi ama�lamaktad&#305;r. Ayr&#305;ca direkt
olarak motor n�ronu korumay&#305; hedefleyen �al&#305;&#351;malar da
vard&#305;r. <span class=SpellE>Mutant</span> SOD1�in ekspresyonunu h�crelere
zarar vermeden <span class=SpellE>viral</span> vekt�rler
arac&#305;l&#305;&#287;&#305;yla ortadan kald&#305;rmaya y�nelik
�al&#305;&#351;malar hayvan deneylerinde olumlu sonu� vermi&#351;tir. Bu y�ntem
insanda denenme a&#351;amas&#305;ndad&#305;r. <span class=SpellE>N�ronal</span>
<span class=SpellE>inkl�zyonlar&#305;n</span> varl&#305;&#287;&#305;, <span
class=SpellE>mitokondriyal</span> <span class=SpellE>disfonksiyon</span>, <span
class=SpellE>mikroglia</span> aktivasyonu gibi hastal&#305;k s�recinde ortaya
�&#305;kt&#305;&#287;&#305; kan&#305;tlanan patolojik mekanizmalara
y�nelik&nbsp; �al&#305;&#351;malar&#305;n varl&#305;&#287;&#305; da
bilinmektedir. Bug�n i�in ALS tedavisi i�in, etkisi k&#305;s&#305;tl&#305; da
olsa, ge�erli oldu&#287;u bilinen <span class=SpellE><i>Riluzole</i></span>
motor n�ron �l�m�ne neden oldu&#287;u kan&#305;tlanan <span class=SpellE>eksitotoksisite</span>
teorisi sonucunda geli&#351;tirilmi&#351;tir. <span class=SpellE><i>Riluzole</i></span>
sodyum ve y�ksek-voltajl&#305; kalsiyum kanal blokaj&#305; yan&#305;nda <span
class=SpellE>glutamat</span> resept�r blokaj&#305; yaparak etkisini g�stermektedir.
�teden beri <span class=SpellE>n�rodejeneratif</span> hastal&#305;klar i�in s�z
konusu edilen k�k h�cre tedavisi son g�nlerde ALS i�in de ad&#305;ndan olduk�a
s�z ettirmektedir. Hastalara uygulanabilmesi i�in daha �ok ara&#351;t&#305;rma
ve �al&#305;&#351;ma yap&#305;lmas&#305; gerekmektedir. <span class=SpellE>Embriyonik</span>
k�k h�creler in <span class=SpellE>vitro</span> olarak motor n�ron benzeri
h�crelere d�n�&#351;mektedir. Bu �al&#305;&#351;malar hayvan deneyi d�zeyinde
olumlu sonu�lar verse de insanlara uygulamak ve varsa olumlu
sonu�lar&#305;n&#305; g�rmek i�in zamana ihtiya� vard&#305;r. Daha �ok kemik
ili&#287;i gibi <span class=SpellE>n�ral</span> dokuya da d�n�&#351;me
yetene&#287;i olan <span class=SpellE>multipotent</span> <span class=SpellE>projenit�r</span>
h�crelerin kullan&#305;ld&#305;&#287;&#305; �al&#305;&#351;malar gelecek vaat
edebilir. &nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span class=SpellE><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>ALS�de</span></b></span><b><span lang=TR style='font-size:14.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'> Bak&#305;m </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G�z kaslar&#305; hari� hemen t�m istemli
kaslar&#305; tutan ve <span class=SpellE>atrofiye</span> yol a�an bu k�t� <span
class=SpellE>prognozlu</span>, a&#287;&#305;r kas hastal&#305;&#287;&#305;nda
hen�z tedavi olana&#287;&#305; bulunmad&#305;&#287;&#305;ndan bak&#305;m (<span
class=SpellE>management</span>) b�y�k �nem ta&#351;&#305;maktad&#305;r. ALS
ortalama 3-4 y&#305;l i�inde e&#287;er yard&#305;mc&#305; solunum
olanaklar&#305; kullan&#305;lmazsa, �l�me g�t�rmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tan&#305;y&#305; bildirmek</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> ciddi bir sorundur ve
�ok k�t� bir <span class=SpellE>prognoza</span> sahip olan b�yle bir
hastal&#305;&#287;&#305;, o hastal&#305;&#287;&#305; ta&#351;&#305;yan kimseye
a�&#305;klaman&#305;n do&#287;ru olup olmad&#305;&#287;&#305;
tart&#305;&#351;mal&#305;d&#305;r. Bu sorunun cevab&#305;, toplumlar&#305;n
k�lt�rel �zelliklerine g�re de&#287;i&#351;mektedir. Bir�ok bat&#305; �lkesinde
hastal&#305;kla ilgili ger�ekler hastaya a�&#305;klanmaktad&#305;r. Bu, orada
ola&#287;an ve beklenen bir davran&#305;&#351;ken, bizim �lkemizde ise
�o&#287;unlukla b�yle bir ger�ekle y�zle&#351;meye haz&#305;rl&#305;kl&#305;
ki&#351;ilik �zellikleri bulunmayabilmektedir. �lkemizde, n�rologlar hastaya
genellikle ciddi bir hastal&#305;k oldu&#287;unu, uzun s�rebilece&#287;ini
s�ylemekte, ancak birka� y&#305;l i�inde �ld�r�c� olabilece&#287;ini
a�&#305;klamamaktad&#305;r. Bunu uygun bir dille ve aile bireyleri i�inde uygun
buldu&#287;umuz ki&#351;i <span class=SpellE>ya</span> da ki&#351;ilere
s�ylemeyi tercih etmekteyiz.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bak&#305;m &#304;lkeleri</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALS hastas&#305;n&#305;n gerekti&#287;i gibi
bak&#305;m&#305;, her &#351;eyden �nce bu konuda ciddi bir deneyimin varl&#305;&#287;&#305;n&#305;
gerektirmektedir. Hastal&#305;k semptomlar&#305;n&#305;n kontrol�, solunum ve
beslenme yetersizli&#287;i ile ba&#351; edebilmek, <span class=SpellE>palyatif</span>
bak&#305;m, �ncelikli direktifler (<span class=SpellE>advance</span> <span
class=SpellE>directive</span>), �tenazi, profesyonel ev <span class=SpellE>vizitleri</span>
ve <span class=SpellE>supervizyonu</span> (<span class=SpellE>hospice</span>)
konular&#305; bu b�l�mde&nbsp; ayr&#305; <span class=SpellE>ayr&#305;</span>
i&#351;lenecektir. Ba&#351;lang&#305;�ta &#351;unu belirtmek �ok yerinde olur:
ALS hastas&#305;n&#305;n bak&#305;m&#305; ancak <span class=SpellE>multidisipliner</span>
bir yap&#305;lanma i�inde ger�ekle&#351;tirilebilir. Bu �ok y�nl�
bak&#305;m&#305;n sadece n�rolog taraf&#305;ndan y�r�t�lmesi d�&#351;�n�lemez.
N�rolog, ekibin tan&#305; koyan, var olan ila� tedavisini d�zenleyecek ve ekibe
�nc�l�k edecek ki&#351;i olabilir. Bak&#305;m ekibinde t&#305;bb&#305;n
de&#287;i&#351;ik disiplinlerinden elemanlar yer al&#305;r. Bunlar&#305;
hem&#351;ire, fizyoterapist, ortopedist, diyetisyen, sosyal hizmet uzman&#305;,
solunum terapisti, konu&#351;ma terapisti, psikolog olarak
s&#305;ralayabiliriz. Ger�ekten geli&#351;mi&#351; �lkelerde ALS hastalar&#305;
t�m bu disiplinlerden gelen uzman ki&#351;iler taraf&#305;ndan birlikte
g�r�lmekte ve izlenmektedir. <span class=SpellE>Multidisipliner</span>
bak&#305;m vazge�ilmez bir gereksinimdir. B�yle bir bak&#305;m&#305;
ger�ekle&#351;tirmek e&#287;er iyi bir organizasyon yoksa hi� kolay olmaz. En
ideal bir organizasyon, <span class=SpellE>multidisipliner</span> hizmet veren
bir hastanenin kurulmas&#305; ile ger�ekle&#351;tirilebilir. �rne&#287;in
Milano�da yak&#305;n bir tarihte <span class=SpellE>n�rom�sk�ler</span>
hastal&#305;klar i�in kurulan bir hastane t�m disiplinlerden tam g�n
�al&#305;&#351;an uzmanlar&#305; kadrosunda bulundurmaktad&#305;r. B�ylece bir
ALS hastas&#305; i�in ihtiya� duyulacak n�rolog, solunum terapisti,
konu&#351;ma terapisti,&nbsp; fizyoterapist, me&#351;guliyet terapisti, <span
class=SpellE>palyatif</span> bak&#305;m uzman&#305;, diyetisyen bir arada
bulunmaktad&#305;r. E&#287;er bak&#305;mda rol alacak uzman ki&#351;iler
ayr&#305;, hele birbirinden co&#287;rafi olarak uzak departmanlarda yer
al&#305;yorlarsa, onlardan yararlanmak hasta i�in hi� de kolay de&#287;ildir.
Bizim �lkemizde b�yle bir organizasyon ve yap&#305;lanma yoktur. T�m ihtiya�lar&#305;
kar&#351;&#305;layacak merkezler de mevcut de&#287;ildir. Sadece
n�rologlar&#305;n bulundu&#287;u bir klinik, bak&#305;m i�in uygun bir yer
olamaz. Baz&#305; �lkelerde �rne&#287;in, &#304;ngiltere�de baz&#305; n�roloji
klinikleri, gerekli bak&#305;m hizmetini vermek �zere (<span class=SpellE>care</span>
<span class=SpellE>center</span>) donat&#305;lm&#305;&#351;t&#305;r. Bu
klinikler, hastan&#305;n hastaneden �&#305;k&#305;p evine d�n�&#351;�nden sonra
onlar&#305; izlemeye devam ederler. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Rehabilitasyonun �ok �st d�zeyde
ger�ekle&#351;tirildi&#287;i bir �lke olan Danimarka�da ALS
hastas&#305;n&#305;n hastanedeki yat&#305;&#351; s�resi sona erince bir
�&#305;k&#305;&#351; program&#305; haz&#305;rlan&#305;r ve ona �cretsiz bir
aspirat�r sa&#287;lan&#305;r. Bu programa g�re hastan&#305;n
ya&#351;ad&#305;&#287;&#305; b�lge hem&#351;iresi ile i&#351;birli&#287;i
yap&#305;l&#305;r. B�yle bir hasta bak&#305;m&#305; i�in yeterli deneyime sahip
olan hem&#351;ire hastay&#305; izlemeyi s�rd�r�r ve klinikle
i&#351;birli&#287;i yapar. ALS bak&#305;m&#305; konusunda iyi
yeti&#351;mi&#351;, deneyim kazanm&#305;&#351; hem&#351;ire �ok �nemli bir ekip
eleman&#305;d&#305;r. Geli&#351;mi&#351; �lkelerde sadece ALS/MNH i�in
uzmanla&#351;m&#305;&#351;, deneyim kazanm&#305;&#351; hem&#351;ireler
bulunmaktad&#305;r. Bizim de bu t�r elemanlara ihtiyac&#305;m&#305;z
oldu&#287;u a�&#305;kt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALS hastas&#305; hastal&#305;&#287;&#305;n ileri
a&#351;amalar&#305;nda ba&#351;l&#305;ca iki sorunla kar&#351;&#305;la&#351;&#305;r:
</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>1) Solunum, 2) Beslenme yetersizli&#287;i;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Solunum</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Solunum kaslar&#305; ve diyafram
zay&#305;flad&#305;&#287;&#305; zaman hastada sabahlar&#305; <span
class=SpellE>ba&#351;a&#287;r&#305;lar&#305;</span>,
i&#351;tahs&#305;zl&#305;k, uyku d�zensizli&#287;i, halsizlik, letarji gibi
belirtiler ba&#351; g�sterir. Diyafram zay&#305;flay&#305;nca �zellikle yatar
durumda solunum yetersizli&#287;i ortaya �&#305;kar. B�yle bir durumda solunum
terapisti <span class=SpellE>spirometre</span> ile solunum �l��mleri
yapmal&#305;d&#305;r. <span class=SpellE>Vital</span> kapasitenin
d�&#351;t�&#287;� tespit edilince, hastaya bir solunum aleti ile a&#287;&#305;z
ve burundan maske ile hava verme <span class=SpellE>endikasyonu</span> ortaya
�&#305;kar. Bu tedavi <span class=SpellE><i>non</i></span><i>-<span
class=SpellE>invasif</span> <span class=SpellE>ventilasyon</span></i> olarak
isimlendirilmektedir. B�yle bir hastan&#305;n yak&#305;ndan izlenmesi gerekir.
Aletin kullan&#305;m zamanlar&#305; ve s�relerinin tayini gerekecektir. Solunum
yetersizli&#287;i b�yle <span class=SpellE>non</span>-<span class=SpellE>invasif</span>
y�ntemle kontrol edilemeyecek duruma gelebilir. O zaman yap&#305;lacak &#351;ey
<span class=SpellE>trakeostomidir</span>. &nbsp;<span class=SpellE>Trakeostomi</span>
arzu edilen bir &#351;ey de&#287;ildir ancak b�yle bir zorunluluk ortaya
�&#305;kabilir. Baz&#305; �lkelerde olabildi&#287;ince <span class=SpellE>trakeostomiden</span>
ka�&#305;n&#305;lmaktad&#305;r. Bu m�dahale ile hastan&#305;n kolayl&#305;kla �<span
class=SpellE>locked</span>-in� durumuna girebilece&#287;i gerek�esi, bu
�ekingenli&#287;e yol a�maktad&#305;r. <span class=SpellE>Trakeostomili</span>
ALS hastas&#305; bir �nceki <span class=SpellE>duurumuna</span> g�re daha da
yak&#305;n bir ilgi ve bak&#305;m&#305; gerektirir. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Terminal d�nemde<i> morfin</i>in �ok iyi bir �are
oldu&#287;u ileri s�r�lmektedir. Her ne kadar morfin solunum <span
class=SpellE>supresyonu</span> yapsa da hastay&#305; rahat ettirmekte, <span
class=SpellE>anksiyeteyi</span> azaltmaktad&#305;r. Bu y�zden tercih edilen bir
tedavidir.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Beslenme ve Diyet D�zenlemesi </span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALS hastas&#305;n&#305;n beslenmesi �ok �nemlidir.
Yutma g��l�&#287;� g�steren hastada dikkat edilecek &#351;eyler vard&#305;r.
Salata, �i&#287; sebze, kuru bisk�vi, sulu �orba, kuru g&#305;dalar, sert
g&#305;dalar- ceviz, f&#305;nd&#305;k gibi-, baharatl&#305; yemekler,
k&#305;l�&#305;kl&#305; sebzelerden ka�&#305;nmal&#305;d&#305;r. Beslenme
s&#305;kl&#305;&#287;&#305;n&#305; artt&#305;r&#305;p miktar&#305; azaltmak bir
�are olabilir. &#304;yi pi&#351;mi&#351; sebze ve kesilmeye elveri&#351;li hale
gelmi&#351; et, koyu �orba, p�re daha kolay yutulabilir. Su yerine gazozlu,
gazl&#305; i�ecekler tercih edilir. G&#305;da cinsinin hastal&#305;k <span
class=SpellE>prognozunu</span> etkilemesi s�z konusu de&#287;ildir. Bu konudaki
iddialar&#305;n bilimsel bir kan&#305;t&#305; yoktur. Antioksidanlar i�in de
ayn&#305; &#351;ey ge�erlidir.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALS s&#305;kl&#305;kla <span class=SpellE>bulber</span>
kaslar&#305; tuttu&#287;u i�in hastan&#305;n �i&#287;nemesi, yutmas&#305;
bozulmakta, beslenemez duruma gelmekte ve h&#305;zla kilo kaybetmektedir. Bu
durumda onu ba&#351;ka bir yoldan beslemek zorunlulu&#287;u ortaya
�&#305;kmaktad&#305;r. Bu;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:51.75pt;text-indent:-18.0pt;line-height:
150%'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>1)</span><span
lang=TR style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span class=SpellE><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Nazogastrik</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> t�p yolu ile
yap&#305;labilir. Ancak bu uzun s�re kullan&#305;lamaz.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:51.75pt;text-indent:-18.0pt;line-height:
150%'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>2)</span><span
lang=TR style='font-size:7.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>En radikal ��z�m PEG- <span class=SpellE><i>perk�tan</i></span><i>
<span class=SpellE>endoskopik</span> <span class=SpellE>gastrostomi<span
style='font-style:normal'>dir</span></span></i>. Yani <span class=SpellE>endoskopi</span>
deste&#287;i ile kar&#305;n duvar&#305;nda yap&#305;lacak bir <span
class=SpellE>insizyonla</span> bir t�p mideye yerle&#351;tirilir ve hasta bu
yolla beslenir. Bu y�ntem kanserli ve fel�li hastalarda
kullan&#305;lm&#305;&#351;t&#305;r. ALS hastalar&#305;nda da s&#305;kl&#305;kla
bir zorunluluk olarak ortaya �&#305;kmaktad&#305;r. <span class=SpellE>Vital</span>
kapasite % 50�ye d�&#351;meden �nce yap&#305;lmas&#305; tercih edilmelidir. PEG
de elbette deneyimli eller taraf&#305;ndan yap&#305;lmal&#305; ve hasta
dikkatle izlenmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Fizyoterapi</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hasta bak&#305;m&#305;nda fizyoterapistlerin rol�,
g�nl�k aktiviteyi de&#287;erlendirmek, <span class=SpellE>mobiliteyi</span>
sa&#287;lamak gerekiyorsa baz&#305; aletler kullanmak, tuvalet ve banyo
ihtiya�lar&#305;n&#305;n giderilmesi i�in evde gerekli adaptasyonlar&#305;
ger�ekle&#351;tirmektir. <span class=SpellE>Kontrakt�rleri</span> �nlemek �zere
egzersiz programlar&#305; yapmak, bunlara ek olarak solunum egzersizleri
uygulamak, y�r�meyi sa&#287;lamak i�in gerekiyorsa baston ve <span
class=SpellE>ortez</span> ( <span class=SpellE>splints</span> ) aletleri
kullanmak do&#287;ru olacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;leti&#351;im ve Konu&#351;ma</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALS hastas&#305; konu&#351;amaz kendini ifade
edemez hale gelebilir. Bu durumda onun ileti&#351;im sa&#287;layabilmesi i�in
uygulanacak �e&#351;itli y�ntemler vard&#305;r. En basiti harflerden
olu&#351;an bir tabloda bir &#305;&#351;&#305;kla harf se�ip kelimeler
olu&#351;turarak kendini ifade etmesidir. Tu&#351;lara bas&#305;l&#305;nca
kelimeler �&#305;karan sesli konu&#351;ma aletleri bulunmaktad&#305;r.
Bilgisayar&#305; e&#287;er eller g��s�zse g�z hareketleri ile, ekrandaki
klavyeyi kullanarak mesaj verme olana&#287;&#305;n&#305; sa&#287;layan ileri
teknoloji de mevcuttur. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Psikolog Deste&#287;i </span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastalar&#305;n bir b�l�m�nde <span class=SpellE>kognitif</span>
bozukluklar, uyum zorluklar&#305; g�r�lebilir. <span class=SpellE>Anksiyete</span>
geli&#351;ebilir. Ku&#351;kusuz hem hasta ki&#351;i hem aile i�in bir
bak&#305;m plan&#305;na ihtiya� vard&#305;r. �te yandan aile ile iyi bir
i&#351;birli&#287;ine girmek zor olabilir. Yurdumuzun ger�eklerinden biri
halk&#305;m&#305;z&#305;n bilimsel yakla&#351;&#305;mlara yatk&#305;n olamay&#305;&#351;&#305;d&#305;r.
&#304;rrasyonel inan&#305;&#351;lar �lkemizde e&#287;itimli ki&#351;ilerde bile
olduk�a yayg&#305;nd&#305;r. &#304;yi bir bak&#305;m yerine olmayan tedaviler
pe&#351;inde ko&#351;anlar �o&#287;unluktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bak&#305;c&#305;lar</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastalar gibi onlara bakanlar da �ok ciddi
sorunlar&#305;n yarat&#305;c&#305;s&#305; olabilirler, ALS hastas&#305;
bak&#305;m&#305;nda bu sorunlar uluslararas&#305; toplant&#305;larda �nemle ele
al&#305;nmaktad&#305;r. Gittik�e ilerleyen a&#287;&#305;r bir hastal&#305;k ve
ona s�rekli bak&#305;m hizmeti veren insanlar s�z konusudur. Bunlar
�o&#287;unlukla karde&#351;i, k&#305;z&#305;, e&#351;i, annesi gibi aile
bireyleridir. Bazen bak&#305;m g�revi bir g�nde 24 saate yakla&#351;abilir.
Bunun a&#287;&#305;r bir y�k oldu&#287;u ku&#351;ku g�t�rmez. <span
class=SpellE>Mental</span>, fiziksel, psikolojik sorunlar yaratan bir durumdur.
Sevdiklerine b�y�k bir �zveri ile bakarken stres i�ine girmeleri m�mk�nd�r. O
nedenle deste&#287;e ihtiya�lar&#305; vard&#305;r. Geli&#351;mi&#351; �lkelerde
bu ama�lar i�in �e&#351;itli organizasyonlar geli&#351;tirilmekte ve
g�n�ll�lerden olu&#351;an destek gruplar&#305; �nemli hizmetler vermektedir.
Hastalar&#305; ziyaret ederek moral destek sa&#287;lamakta, sorunlar&#305; ve
�areleri payla&#351;maktad&#305;rlar. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Soluklanma, dinlenme ama�l&#305; bak&#305;m (<span
class=SpellE>respite</span> <span class=SpellE>care</span>) olarak ifade
edilebilecek bir yakla&#351;&#305;mda da bir ki&#351;i <span class=SpellE>ya</span>
da bir grup bak&#305;c&#305; <span class=SpellE>ya</span> da bak&#305;m
verenlerin yerini almakta ve onlar&#305; bir s�re (saatler, g�nler)
dinlenmeleri, ferahlamalar&#305; i�in hastan&#305;n bulundu&#287;u yerin
d&#305;&#351;&#305;na g�ndermektedir.&nbsp; O s�renin sonunda
yorgunluklar&#305;n&#305;, y&#305;pranm&#305;&#351;l&#305;klar&#305;n&#305;
geride b&#305;rakm&#305;&#351; olarak bak&#305;m g�revine d�nmeleri
ama�lamaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hasta kaybedildikten sonra sevdiklerinin
kayb&#305;na u&#287;rayan (matem, b�y�k kay&#305;p: <span class=SpellE>breavement</span>)
aileye bir sempati ve destek ziyareti de uygulanmaktad&#305;r.&nbsp; �lkemizde
aile ba&#287;lar&#305; �ok g��l�d�r, ancak bu t�rl� g�n�ll� hizmetleri
ger�ekle&#351;tiremiyoruz. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span class=SpellE><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Palyatif</span></i></span><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Bak&#305;m</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hafifletici �are gibi ifade edilecek bu
yakla&#351;&#305;mda tedavi edemedi&#287;imiz ALS hastalar&#305;nda
semptomlar&#305; olabildi&#287;ince kontrol edebilmek, hastay&#305;
olabildi&#287;ince rahat ettirmek b�y�k �nem ta&#351;&#305;maktad&#305;r.
�rne&#287;in hastada <i>kramplar</i> rahats&#305;z edici olabilir.&nbsp; Bunun
i�in <span class=SpellE>karbamazepin</span>, <span class=SpellE>baklofen</span>
kullan&#305;labilir.&nbsp; Var olan <span class=SpellE><i>fasik�lasyonlar</i></span><i>
</i>kafeinle, alkolle artar, beta <span class=SpellE>blokerler</span> ve <span
class=SpellE>karbamazepin</span> yararl&#305; olabilir. Baz&#305; hastalarda <span
class=SpellE><i>hipersalivasyon</i></span> vard&#305;r. Bu, atropin
damlas&#305; ve <span class=SpellE>amitriptilin</span> ile kontrol alt&#305;na
al&#305;nabilir. Bazen <span class=SpellE>botulinum</span> toksini
uygulamas&#305;na kadar gitmek gerekebilir. B�t�n bu &#351;ikayet ve semptomlar&#305;
y�netebilecek, terminal d�nem bak&#305;m&#305; konusunda
uzmanla&#351;m&#305;&#351; doktor ve hem&#351;irelerin olu&#351;turdu&#287;u
ekipler bulunmaktad&#305;r ve <span class=SpellE>palyatif</span> bak&#305;m bir
uzmanl&#305;k dal&#305; haline gelmektedir. Kanserli hastalarla ba&#351;layan
bu geli&#351;me ALS gibi a&#287;&#305;r seyreden, �l�me g�t�ren hastalarda da
uygulanmaktad&#305;r. Bu elemanlar �ok defa �<span class=SpellE>hospice</span>�<b><u>
</u></b>ad&#305; verilen bak&#305;m merkezlerinde g�rev yapmaktad&#305;rlar.
Hastan&#305;n son d�nemini olabildi&#287;ince ac&#305;s&#305;z,
a&#287;r&#305;s&#305;z ge�irebilmesi �ok �nemlidir. Bu uzman ki&#351;iler
a&#287;r&#305;, <span class=SpellE>anksiyete</span>, solunum yetersizli&#287;i,
uyku d�zensizli&#287;i, salya akmas&#305;, psikolojik bozukluklar gibi
�e&#351;itli semptomlar&#305;n kontrol� i�in gerekli olanlar&#305;
yapmaktad&#305;rlar. Terminal d�nemde morfin s&#305;k�a
kullan&#305;lmaktad&#305;r. �tenazi bu hastalar i�in g�ndemde olan bir
sorundur. Ancak bug�n i�in sadece Hollanda da yasal bir y�ntem olarak
kullan&#305;lmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>�ncelikli Direktifler (<span class=SpellE>Advance</span>
<span class=SpellE>Directives</span>)</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu da ALS bak&#305;m&#305;nda �ok ciddi bir
&#351;ekilde ele al&#305;nan ama bizim �ok yak&#305;n
olmad&#305;&#287;&#305;m&#305;z bir kavramd&#305;r. Pe&#351;in <span
class=SpellE>ya</span> da �ncelikli direktifler olarak terc�me edebiliriz.
Hastan&#305;n ilerleyen hastal&#305;&#287;&#305;n&#305;n, g��s�zl�&#287;�n�n
ileri bir a&#351;amas&#305;nda isteklerini ifade edemeyecek bir duruma
geldi&#287;inde bu d�neme ait istediklerini ve reddettiklerini yaz&#305;l&#305;
olarak belirtmesi ama�lanmaktad&#305;r. Bu belge elbette hukuki bir de&#287;er
ta&#351;&#305;maktad&#305;r ve yasal ge�erlili&#287;i vard&#305;r. Tedavilerin
baz&#305;lar&#305;n&#305; reddetme hakk&#305; vard&#305;r. Ancak t&#305;bbi
olarak, bilimsel olarak uygun olmayan bir tedavi isteme hakk&#305; yoktur.
Bilinci kapand&#305;&#287;&#305; zaman uygulanacak temel bak&#305;m tedbirlerini
(&#305;s&#305;tma, beslenme ) reddedemez <span class=SpellE>ya</span> da �l�m�
�abukla&#351;t&#305;racak ila� isteyemez. Spesifik bir tedavi iste&#287;inde
bulunamaz, ancak �rne&#287;in, <span class=SpellE>trakeostomi</span>
istemedi&#287;ini s�yleyebilir. Hastan&#305;n pe&#351;in (�ncelikli) direktif
belgeleri imzalayabilmesi i�in <span class=SpellE>mental</span> kapasitesinin
yeterli ve 18 ya&#351;&#305;ndan b�y�k olmas&#305; gerekmektedir. Hasta fikrini
de&#287;i&#351;tirebilmekte ve imzalad&#305;&#287;&#305; belgeyi yeniden
d�zenleyebilmektedir. Bizim �lkemizde �<span class=SpellE>hospice</span>�, <span
class=SpellE>palyatif</span> bak&#305;m uzman&#305;, �ncelikli direktif&nbsp;
gibi yap&#305;lanma ve kavramlar hen�z yoktur. Bu hastal&#305;k i�in
kurulmu&#351; merkezlerimiz yoktur. Hastalar te&#351;his konulduktan sonra
olduk�a zor durumda kalmaktad&#305;r ve bak&#305;m ekipleri kurulmu&#351;
de&#287;ildir. Bug�n i�in tan&#305;y&#305; koyan n�rologun ki&#351;isel giri&#351;imleri
ile solunum aleti ve PEG gibi tedbirler az say&#305;daki hasta i�in
ger�ekle&#351;tirilmektedir. &#304;stanbul�daki T�rkiye Kas
Hastal&#305;klar&#305; Derne&#287;i bir evde bak&#305;m ekibi i�in
giri&#351;imde bulunmu&#351;tur. Bu hizmetin iyice geli&#351;tirilmesi,
kurumla&#351;mas&#305; ve t�m �lkeyi kapsamas&#305; i�in devletin,
Sa&#287;l&#305;k Bakanl&#305;&#287;&#305;n&#305;n, Sosyal Hizmet ve �ocuk
Esirgeme Kurumunun ilgisi ve deste&#287;ine ihtiya� vard&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Alternatif &nbsp;Tedavi</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bilimsel, <span class=SpellE>konvansiyonel</span>
tedavilerin d&#305;&#351;&#305;ndaki tedavi giri&#351;imleri bu adla
an&#305;lmaktad&#305;r. Do&#287;al �areler, baz&#305; otlar, bitkisel tedaviler
g�venli olmayabilir. Bir hekimin g�revi sadece olumlu etkisi bilimsel
y�ntemlerle ispatlanm&#305;&#351; olan ila�lar&#305; kullanmakt&#305;r. B�yle
kan&#305;tlar&#305;n bulunmad&#305;&#287;&#305; maddeleri, otlar&#305;
alternatif tedavi ad&#305; alt&#305;nda kullanmak do&#287;ru olamaz. Bilimsel
mant&#305;&#287;&#305; kullanamayan ve bir umut ihtiyac&#305; i�inde olan
hastalar bu tedavileri kolayl&#305;kla benimseyebilirler. Yaz&#305;k ki b�yle
bilim d&#305;&#351;&#305; �neri ve uygulamalar yurdumuzda olduk�a
yayg&#305;nd&#305;r ve neredeyse denetimsizdir. Yine yararl&#305;
olduklar&#305;na dair hi� bir kan&#305;t bulunmayan <span class=SpellE>refleksoloji</span>,
<span class=SpellE>bioenerji</span>, <span class=SpellE>homeopati</span>, <span
class=SpellE>magnetik</span> yatak, akupunktur gibi tedaviler geni&#351; bir
kullan&#305;m alan&#305; bulmakta ve baz&#305; hekimlerce
kullan&#305;lmaktad&#305;r. Bir hastal&#305;kta bir ilac&#305;n etkinli&#287;i
�ok defa y&#305;llar s�ren �al&#305;&#351;ma, ara&#351;t&#305;rma ve denemelerle
ortaya �&#305;kabilir. Hayvan deneylerinden sonra yeterli say&#305;daki hastan&#305;n
bir b�l�m�ne aktif ila�, kontrol grubuna etkisiz madde (<span class=SpellE>plasebo</span>)
verilerek, <span class=SpellE>randomize</span> hasta se�imi ve �ift k�r y�ntemi
ile tedavi s�resi sonunda k&#305;yaslama yap&#305;larak ilac&#305;n
etkinli&#287;i, bunun derecesi <span class=SpellE>ya</span> da etkisizli&#287;i
saptanabilir. Bu ciddi hastal&#305;k i�in tedavi �al&#305;&#351;malar&#305;
aral&#305;ks&#305;z s�rmektedir. K�k h�cre tedavisi, ku&#351;kusuz
ger�ekle&#351;mesinin gecikmemesini diledi&#287;imiz bir umuttur. Bug�n
yap&#305;lacak en do&#287;ru &#351;ey hastalar i�in m�mk�n olan en iyi
bak&#305;m olanaklar&#305;n&#305; yaratabilmek, ya&#351;am kalitesini
y�kseltmek ve bunun i�in devletin deste&#287;ini alabilmek olmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='line-height:150%'><span style='font-family:Tahoma'>KAYNAKLAR<br>
1. Leigh PN. Amyotrophic Lateral Sclerosis. &nbsp;</span><span lang=DE
style='font-family:Tahoma;mso-ansi-language:DE'>&#304;�inde: Eisen AA, Shaw P
(Eds).<br>
</span><span style='font-family:Tahoma'>Motor Neuron Disorders and Related
Diseases. Handbook of Neurology Vol 82.<br>
Amsterdam, Elsevier 2007: 249-278<br>
2. Brown R, Swash M, &nbsp;Psinelli P (Eds). Amyotrophic Lateral Sclerosis. 2nd<br>
Ed. London, Informa-healthcare, 2006<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
style='font-family:Tahoma'><o:p></o:p></span></p>

</div>

</body>

</html>
